Alzheimer's Disease (AD) Clinical Trial
— REALSOCOGOfficial title:
Social-cognitive Functioning: Validation of a New Neuropsychological Test and Prediction of Social Behavioural Disorders in Daily Life
It is now established that disturbances in social cognition are frequent in neurology and that they contribute to the development of social conduct disorders. Their assessment is therefore essential, particularly in order to propose early and adapted care. However, this assessment remains limited today. A new serious game-type test, REALSoCog, has been developed to address the shortcomings of current tools and to highlight disturbances in social behaviors. The latter are not always observed in consultation although they are often reported by caregivers. The objective of this research is therefore to validate the REALSoCog task in a pathological population (currently being standardized in the general population: CER-U, IRB N°: 00012020-115). The clinical interest of this task will be tested with a group of patients suffering from a neurodegenerative disease (Alzheimer's disease (AD), dementia with Lewy bodies (DCL), fronto-temporal lobar degeneration (FTD)) in order to assess its sensitivity and specificity in the detection of social-cognitive disturbances, and in particular in terms of social behaviors (detection of social behavioral disorders reported in daily life). The objective is also to document the socio-cognitive profiles in the mentioned diseases thanks to a more ecological test, and to better understand the links between socio-cognitive processes on the one hand, and individual characteristics on the other hand (e.g. mood and social participation).
Status | Not yet recruiting |
Enrollment | 120 |
Est. completion date | June 1, 2028 |
Est. primary completion date | June 1, 2027 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 90 Years |
Eligibility | Inclusion Criteria: For patients: - Patient aged between 18 and 90 years - Mini Mental State Examination (MMSE) score greater than or equal to 20 - Patient able to express his or her non-opposition to participate in the study in an informed and autonomous manner - Patient with a neurodegenerative pathology: FTD, AD or LBD. For caregivers: - Over 18 years of age - Regular contact with the patient (= 2 times per month) Exclusion Criteria: For patients: - Neurological or psychiatric comorbidity - Notable sensory disorders (e.g., profound or total deafness, age-related macular degeneration, blindness, etc.) that may interfere with experimental completion. - Opposition to participation in the study |
Country | Name | City | State |
---|---|---|---|
France | Hôpital de la Pitié-Salpêtrière | Paris |
Lead Sponsor | Collaborator |
---|---|
Assistance Publique - Hôpitaux de Paris |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | rate of inappropriate behavioural intentions | It is measured by the REALSoCog task through a question asking the participant to specify his behavioral intention in the case where he would have declared his intention to act in front of the social situation presented. These questions are asked for each social situation presented, i.e. for a total of 16 situations | 1 hour and a half | |
Secondary | Assessment of Moral cognition | The ability to detect moral transgressions, the ability to detect conventional transgressions, and the ability to detect control situations (non-transgressive situations) are measured by the question "Does this situation seem appropriate or inappropriate to you?" asked after each REALSoCog situation. The severity judgment of moral transgressions and the severity judgment of conventional transgressions are measured by the question "How inappropriate does it [the situation] seem to you?" asked after each response characterizing the situation presented as inappropriate in REALSoCog. | 1 hour and a half | |
Secondary | Evaluation of Empathy and emotional reactivity | The intensity of emotional empathy and the intensity of emotional reactivity are measured by the question "How much are you affected by the situation? This question is asked after each experimental situation of REALSoCog (i.e. situations involving a transgression and situations constructed to elicit empathy), i.e. for 10 situations.
The valence and congruence of the emotions felt are measured by the question "The emotion you feel at the sight of this situation is: 1 (very negative) to 5 (very positive)". This question is asked after each experimental situation of REALSoCog (i.e. situations involving a transgression and situations constructed to elicit empathy), i.e. for 10 situations. |
1 hour and a half | |
Secondary | Assessment of theory of mind | The ability to detect the intentionality of an action is measured by the question "Is the behavior of the [main protagonist in the situation] intentional? Yes / No". This question is asked for 5 REALSoCog situations.
The ability to characterize the valence of this intention and the average valence of the attributed intentions is measured by the question "In your opinion the intention is: 1 (very malicious) to 5 (very benevolent)". This question is asked for 5 REALSoCog situations. The ability to infer an affect to others is measured by the question "How does [main protagonist of the situation] feel?". This question is asked for 8 REALSoCog situations. The intensity of the affect attributed to others is measured by the question "How does [main protagonist of the situation] feel about [subject's response to the previous question]?" This question is asked for 8 REALSoCog situations. |
1 hour and a half |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02503501 -
Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease
|
Phase 2 | |
Recruiting |
NCT02854033 -
Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3)
|
||
Completed |
NCT02593318 -
Trial of Oxaloacetate in Alzheimer's Disease (TOAD)
|
Phase 1 | |
Completed |
NCT02681172 -
Impact of FBB PET Amyloid Imaging in Change of Diagnosis in Patients With AD
|
Phase 4 | |
Completed |
NCT02264899 -
MEMENTO-VAScular COmponents of Dementia
|
N/A | |
Completed |
NCT02531360 -
Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Tauopathies
|
Phase 0 | |
Recruiting |
NCT04570761 -
Effects of Auditory Brain Stimulation by "Pink Noise" on Memory Capacities in Alzheimer's Disease: Proof of Concept Study
|
N/A | |
Not yet recruiting |
NCT05592678 -
δ in Dementia Clinical Trials
|
Phase 2/Phase 3 | |
Recruiting |
NCT05059158 -
Amyloid-β Clearance Mechanisms in Alzheimer's Disease
|
||
Recruiting |
NCT02832921 -
Cognitive-motor Intervention Using Virtual Reality for Middle-aged Individuals at High Dementia Risk
|
N/A | |
Completed |
NCT02370524 -
Quantitative Evaluation of [18F]T807 as a Potential PET Radioligand for Imaging Tau in Patients With Alzheimer's Disease
|
Phase 1 | |
Completed |
NCT01780519 -
The Cognitive Effects of Lorazepam in Healthy Older Individuals With TOMM40 Variable-length Polymorphisms
|
Phase 1 | |
Completed |
NCT02103894 -
Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects
|
Phase 1 | |
Completed |
NCT03802162 -
A Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-355
|
Phase 1 | |
Completed |
NCT01231971 -
Alzheimer's Disease Neuroimaging Initiative 2
|
||
Recruiting |
NCT05291234 -
A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer's Disease
|
Phase 2 | |
Active, not recruiting |
NCT05771428 -
Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer's Disease
|
Phase 2 | |
Recruiting |
NCT06114745 -
A Trial of SHR-1707 Infusion in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease
|
Phase 1 |